Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • nemolizumab

    - PMLiVE

    Galderma’s Nemluvio rapidly relieves atopic dermatitis and prurigo nodularis symptoms

    Some patients found the treatment reduced itch and sleep disturbance within just two days

    - PMLiVE

    Galderma shares positive long-term data for Nemluvio in prurigo nodularis

    The chronic skin disorder is estimated to affect up to 181,000 people in the US

    - PMLiVE

    Galderma shares positive two-year results for Nemluvio in atopic dermatitis

    The chronic inflammatory skin disease affects more than 230 million people worldwide

    - PMLiVE

    MHRA approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

    The drug has been authorised to treat patients with moderate-to-severe cases of the skin diseases

    EU flag

    EC approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis

    Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha

    EU flag

    CHMP recommends Galderma’s nemolizumab for atopic dermatitis and prurigo nodularis

    The drug has been recommended for use in patients with moderate-to-severe cases of the skin diseases

    - PMLiVE

    Galderma announces positive late-stage results for nemolizumab in prurigo nodularis

    The chronic skin condition is estimated to affect up to 181,000 people in the US

    - PMLiVE

    FDA approves Galderma’s IL-31 inhibitor Nemluvio to treat prurigo nodularis in adults

    The chronic skin condition is estimated to affect up to 181,000 people in the US

    - PMLiVE

    Galderma’s nemolizumab shows promise in phase 3 prurigo nodularis trial

    The condition affects more than 70 out of every 100,000 adults aged 18 to 64 years in the US

    - PMLiVE

    Positive results for Sanofi/Regeneron’s Dupixent published in Nature Medicine

    The biologic was shown to significantly improve uncontrolled prurigo nodularis symptoms

    - PMLiVE

    Sanofi and Regeneron’s Dupixent granted EC approval for prurigo nodularis

    Two phase 3 trials showed a reduction in itch, skin lesions and health-related quality of life

    - PMLiVE

    Sanofi/Regeneron’s Dupixent receives CHMP recommendation for prurigo nodularis

    Two phase 3 trials showed a reduction in itch, skin lesions and health-related quality of life

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links